Bank of America Forecasts Strong Price Appreciation for Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by research analysts at Bank of America from $1,293.00 to $1,294.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s target price would indicate a potential upside of 35.43% from the stock’s previous close.

A number of other brokerages have also commented on LLY. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. CICC Research increased their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Barclays started coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Stock Up 3.9%

NYSE LLY opened at $955.45 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a market cap of $902.73 billion, a PE ratio of 41.63, a PEG ratio of 1.07 and a beta of 0.51. The firm has a 50-day simple moving average of $999.28 and a 200 day simple moving average of $966.87. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the company posted $5.32 earnings per share. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently modified their holdings of the company. Maryland Capital Advisors Inc. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $29,000. Finally, Steph & Co. grew its holdings in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves Foundayo (orforglipron), Lilly’s once‑daily oral GLP‑1 for obesity — expands the company’s weight‑loss franchise with an easy‑to‑scale pill that the company plans to sell via LillyDirect (low advertised self‑pay price and payer coverage could accelerate adoption). Lilly’s weight-loss pill wins US approval (Reuters)
• Positive Sentiment: Lilly agreed to buy Centessa (initial ~$6.3B, up to ~$7.8B with milestones), broadening into sleep‑wake and narcolepsy assets — strategic diversification that reduces reliance on GLP‑1 revenue and bolsters mid‑term growth optionality. Eli Lilly to Buy Centessa (CNBC)
• Positive Sentiment: Unusually large call‑option volume and targeted bullish trades around LLY indicate investor enthusiasm and short‑term upside conviction following the FDA approval and M&A news. This derivatives activity can amplify near‑term price moves. Options Traders Pick Up Pharma Stock After Eli Lilly Buyout (Yahoo)
• Neutral Sentiment: Competitive dynamics: Novo Nordisk is responding (subscription pricing, product tweaks) and remains a formidable rival in GLP‑1s — Foundayo’s approval intensifies the duel but outcomes depend on clinical preference, pricing, and payer decisions. Wegovy vs. Foundayo (TipRanks)
• Negative Sentiment: Policy risk: Lilly’s CEO publicly opposed codifying the Trump administration’s Most Favored Nations drug‑pricing deals into law — signals potential tension with government pricing initiatives that could affect future pricing/reimbursement. Lilly opposes MFN codification (CNBC)
• Negative Sentiment: Deal scrutiny: a law firm has opened an investor probe into the Centessa sale price/process — potential legal or shareholder hurdles could slow closing or create contingencies tied to the transaction. Centessa investor alert (BusinessWire)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.